title: Hepatitis C virus genotype 4: Genotype 1's little brother.
abstract: Treatment for hepatitis C virus genotype 4 infection has undergone a major advance over the past 5 years with the emergence of direct-acting antiviral agents. Previously, genotype 4 treatment had been limited to the combination of pegylated interferon and ribavirin, with low rates of sustained virological response. The combinations of new direct-acting agents have resulted in a radical improvement in hepatitis C therapy. Much of the currently available efficacy and safety information in the treatment of genotype 4 has been extrapolated through the results of genotype 1. In this report, we review the efficacy and safety data obtained in recent studies focusing on genotype 4 patients, including special populations, such as those with decompensated cirrhosis.
authors.affiliation: Liver Unit, Internal Medicine Department, Vall d'Hebron Hospital, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Llaneras
authors.affiliation: Liver Unit, Internal Medicine Department, Vall d'Hebron Hospital, Barcelona, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto Carlos III, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Riveiro-Barciela
authors.affiliation: Liver Unit, Internal Medicine Department, Vall d'Hebron Hospital, Barcelona, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto Carlos III, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Buti
authors.affiliation: Liver Unit, Internal Medicine Department, Vall d'Hebron Hospital, Barcelona, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto Carlos III, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Esteban
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D005449:Fluorenes / Q000627:therapeutic use; D005838:Genotype; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000069616:Simeprevir / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000627:therapeutic use; D000072230:Sustained Virologic Response
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; C586541:ledipasvir; D000069616:Simeprevir; D000069474:Sofosbuvir
keywords: daclatasvir; genotype 4; hepatitis C; ledipasvir; simeprevir; sofosbuvir